162 related articles for article (PubMed ID: 24436453)
1. Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trial.
Wei X; Hunt G; Abdool Karim SS; Naranbhai V; Sibeko S; Abdool Karim Q; Li JF; Kashuba AD; Werner L; Passmore JA; Morris L; Heneine W; Johnson JA
J Infect Dis; 2014 Jun; 209(12):1916-20. PubMed ID: 24436453
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Abdool Karim Q; Abdool Karim SS; Frohlich JA; Grobler AC; Baxter C; Mansoor LE; Kharsany AB; Sibeko S; Mlisana KP; Omar Z; Gengiah TN; Maarschalk S; Arulappan N; Mlotshwa M; Morris L; Taylor D;
Science; 2010 Sep; 329(5996):1168-74. PubMed ID: 20643915
[TBL] [Abstract][Full Text] [Related]
3. Limited HIV-1 superinfection in seroconverters from the CAPRISA 004 Microbicide Trial.
Redd AD; Mullis CE; Wendel SK; Sheward D; Martens C; Bruno D; Werner L; Garrett NJ; Abdool Karim Q; Williamson C; Porcella SF; Quinn TC; Abdool Karim SS
J Clin Microbiol; 2014 Mar; 52(3):844-8. PubMed ID: 24371237
[TBL] [Abstract][Full Text] [Related]
4. No evidence for selection of HIV-1 with enhanced gag-protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial.
Chopera DR; Mann JK; Mwimanzi P; Omarjee S; Kuang XT; Ndabambi N; Goodier S; Martin E; Naranbhai V; Karim SA; Karim QA; Brumme ZL; Ndung'u T; Williamson C; Brockman MA;
PLoS One; 2013; 8(8):e71758. PubMed ID: 24015191
[TBL] [Abstract][Full Text] [Related]
5. Reformulated tenofovir gel for use as a dual compartment microbicide.
Dezzutti CS; Rohan LC; Wang L; Uranker K; Shetler C; Cost M; Lynam JD; Friend D
J Antimicrob Chemother; 2012 Sep; 67(9):2139-42. PubMed ID: 22581908
[TBL] [Abstract][Full Text] [Related]
6. Women with pregnancies had lower adherence to 1% tenofovir vaginal gel as HIV preexposure prophylaxis in CAPRISA 004, a phase IIB randomized-controlled trial.
Matthews LT; Sibeko S; Mansoor LE; Yende-Zuma N; Bangsberg DR; Karim QA
PLoS One; 2013; 8(3):e56400. PubMed ID: 23472071
[TBL] [Abstract][Full Text] [Related]
7. Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel.
Naranbhai V; Abdool Karim SS; Altfeld M; Samsunder N; Durgiah R; Sibeko S; Abdool Karim Q; Carr WH;
J Infect Dis; 2012 Oct; 206(7):993-1001. PubMed ID: 22829639
[TBL] [Abstract][Full Text] [Related]
8. Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial.
Mureithi MW; Poole D; Naranbhai V; Reddy S; Mkhwanazi NP; Sibeko S; Werner L; Abdool Karim Q; Abdool Karim S; Ndung'u T; Altfeld M;
J Acquir Immune Defic Syndr; 2012 Jun; 60(2):124-7. PubMed ID: 22362152
[TBL] [Abstract][Full Text] [Related]
9. Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue.
Dobard C; Sharma S; Martin A; Pau CP; Holder A; Kuklenyik Z; Lipscomb J; Hanson DL; Smith J; Novembre FJ; García-Lerma JG; Heneine W
J Virol; 2012 Jan; 86(2):718-25. PubMed ID: 22072766
[TBL] [Abstract][Full Text] [Related]
10. Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial.
Sokal DC; Karim QA; Sibeko S; Yende-Zuma N; Mansoor LE; Baxter C; Grobler A; Frolich J; Kharsany AB; Miya N; Mlisana K; Maarshalk S; Karim SS
Antivir Ther; 2013; 18(3):301-10. PubMed ID: 22914267
[TBL] [Abstract][Full Text] [Related]
11. Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness.
Kashuba AD; Gengiah TN; Werner L; Yang KH; White NR; Karim QA; Abdool Karim SS
J Acquir Immune Defic Syndr; 2015 Jul; 69(3):264-9. PubMed ID: 26181703
[TBL] [Abstract][Full Text] [Related]
12. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments.
Hendrix CW; Chen BA; Guddera V; Hoesley C; Justman J; Nakabiito C; Salata R; Soto-Torres L; Patterson K; Minnis AM; Gandham S; Gomez K; Richardson BA; Bumpus NN
PLoS One; 2013; 8(1):e55013. PubMed ID: 23383037
[TBL] [Abstract][Full Text] [Related]
13. Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa.
Williams BG; Abdool Karim SS; Karim QA; Gouws E
J Acquir Immune Defic Syndr; 2011 Oct; 58(2):207-10. PubMed ID: 21654503
[TBL] [Abstract][Full Text] [Related]
14. Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial.
Mansoor LE; Abdool Karim Q; Mngadi KT; Dlamini S; Montague C; Nkomonde N; Mvandaba N; Baxter C; Gengiah TN; Samsunder N; Dawood H; Grobler A; Frohlich JA; Abdool Karim SS
Trials; 2014 Dec; 15():496. PubMed ID: 25527071
[TBL] [Abstract][Full Text] [Related]
15. Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide.
Ngandu NK; Carlson JM; Chopera DR; Ndabambi N; Abdool Karim Q; Abdool Karim S; Williamson C
J Acquir Immune Defic Syndr; 2017 Sep; 76(1):43-47. PubMed ID: 28797020
[TBL] [Abstract][Full Text] [Related]
16. CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck.
Valley-Omar Z; Sibeko S; Anderson J; Goodier S; Werner L; Arney L; Naranbhai V; Treurnicht F; Abrahams MR; Bandawe G; Swanstrom R; Karim QA; Karim SS; Williamson C
J Infect Dis; 2012 Jul; 206(1):35-40. PubMed ID: 22551813
[TBL] [Abstract][Full Text] [Related]
17. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention.
van der Straten A; Van Damme L; Haberer JE; Bangsberg DR
AIDS; 2012 Apr; 26(7):F13-9. PubMed ID: 22333749
[TBL] [Abstract][Full Text] [Related]
18. Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence.
Celum C; Baeten JM
Curr Opin Infect Dis; 2012 Feb; 25(1):51-7. PubMed ID: 22156901
[TBL] [Abstract][Full Text] [Related]
19. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial.
Karim QA; Kharsany AB; Frohlich JA; Baxter C; Yende N; Mansoor LE; Mlisana KP; Maarschalk S; Arulappan N; Grobler A; Sibeko S; Omar Z; Gengiah TN; Mlotshwa M; Samsunder N; Karim SS
Trials; 2011 Mar; 12():67. PubMed ID: 21385354
[TBL] [Abstract][Full Text] [Related]
20. HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial.
Garrett NJ; Werner L; Naicker N; Naranbhai V; Sibeko S; Samsunder N; Gray C; Williamson C; Morris L; Abdool-Karim Q; Abdool-Karim SS
J Acquir Immune Defic Syndr; 2015 Jan; 68(1):55-61. PubMed ID: 25247433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
